title: BLA to vHPC inputs modulate anxiety-related behaviors.
abstract: The basolateral amygdala (BLA) and ventral hippocampus (vHPC) have both been implicated in mediating anxiety-related behaviors, but the functional contribution of BLA inputs to the vHPC has never been directly investigated. Here we show that activation of BLA-vHPC synapses acutely and robustly increased anxiety-related behaviors, while inhibition of BLA-vHPC synapses decreased anxiety-related behaviors. We combined optogenetic approaches with in vivo pharmacological manipulations and ex vivo whole-cell patch-clamp recordings to dissect the local circuit mechanisms, demonstrating that activation of BLA terminals in the vHPC provided monosynaptic, glutamatergic inputs to vHPC pyramidal neurons. Furthermore, BLA inputs exerted polysynaptic, inhibitory effects mediated by local interneurons in the vHPC that may serve to balance the circuit locally. These data establish a role for BLA-vHPC synapses in bidirectionally controlling anxiety-related behaviors in an immediate, yet reversible, manner and a model for the local circuit mechanism of BLA inputs in the vHPC.
authors: The Picower Institute for Learning and Memory, Department of Brain & Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
authors: Ada C
authors: AC
authors: Felix-Ortiz
authors: Anna
authors: A
authors: Beyeler
authors: Changwoo
authors: C
authors: Seo
authors: Christopher A
authors: CA
authors: Leppla
authors: Craig P
authors: CP
authors: Wildes
authors: Kay M
authors: KM
authors: Tye
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000679:Amygdala / Q000503:physiopathology*; D000818:Animals; D001007:Anxiety / Q000235:genetics / Q000473:pathology*; D001426:Bacterial Proteins / Q000235:genetics; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000235:genetics; D000075402:Channelrhodopsins; D004195:Disease Models, Animal; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005106:Exploratory Behavior; D025602:Halorhodopsins / Q000235:genetics / Q000378:metabolism; D006624:Hippocampus / Q000166:cytology / Q000503:physiopathology*; D066298:In Vitro Techniques; D008164:Luminescent Proteins / Q000235:genetics; D008297:Male; D018782:Maze Learning; D008564:Membrane Potentials / Q000235:genetics / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009434:Neural Pathways / Q000502:physiology*; D009474:Neurons / Q000502:physiology; D026941:Sodium Channel Blockers / Q000494:pharmacology; D013569:Synapses / Q000502:physiology; D013779:Tetrodotoxin / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D001426:Bacterial Proteins; D000075402:Channelrhodopsins; D018691:Excitatory Amino Acid Antagonists; D025602:Halorhodopsins; D008164:Luminescent Proteins; D026941:Sodium Channel Blockers; C054562:yellow fluorescent protein, Bacteria; D013779:Tetrodotoxin; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; C056639:2-amino-5-phosphopentanoic acid; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D014633:Valine
references: Science. 2009 Mar 13;323(5920):1492-6
references: 19286560
references: Neuron. 2013 Mar 6;77(5):955-68
references: 23473324
references: Nat Rev Neurosci. 2012 Mar 20;13(4):251-66
references: 22430017
references: Cell. 2010 Apr 2;141(1):154-165
references: 20303157
references: Nature. 2010 Nov 11;468(7321):277-82
references: 21068837
references: Behav Brain Res. 2002 Aug 21;134(1-2):49-57
references: 12191791
references: Nature. 2006 Feb 16;439(7078):865-70
references: 16482160
references: J Comp Neurol. 1999 Jan 11;403(2):229-60
references: 9886046
references: Neuron. 2010 Jan 28;65(2):257-69
references: 20152131
references: J Neurosci. 2010 Jan 6;30(1):116-25
references: 20053894
references: Arch Gen Psychiatry. 2009 Dec;66(12):1361-72
references: 19996041
references: J Neurosci. 1999 Dec 15;19(24):10869-76
references: 10594068
references: Neuron. 2011 Sep 8;71(5):898-910
references: 21903082
references: Pharmacol Biochem Behav. 1996 May;54(1):123-8
references: 8728549
references: Physiol Behav. 1999 Jan 1-15;65(4-5):739-51
references: 10073475
references: Nature. 2010 Nov 11;468(7321):270-6
references: 21068836
references: Biol Psychiatry. 2004 May 1;55(9):897-903
references: 15110733
references: Nature. 2011 Mar 17;471(7338):358-62
references: 21389985
references: Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10825-30
references: 12149439
references: Biol Psychiatry. 2002 Jan 1;51(1):68-80
references: 11801232
references: Behav Brain Res. 2003 Feb 17;139(1-2):197-213
references: 12642189
references: Nat Neurosci. 2007 May;10(5):663-8
references: 17435752
references: Behav Neurosci. 2004 Feb;118(1):63-78
references: 14979783
references: J Comp Neurol. 1995 May 29;356(2):288-310
references: 7629320
references: J Neurosci. 1995 May;15(5 Pt 1):3622-39
references: 7751934
references: PLoS One. 2011 Apr 11;6(4):e18739
references: 21494567
references: Nat Neurosci. 2004 Mar;7(3):278-85
references: 14758364